ResMed Stock (RMD): A Mission-Critical Healthcare Platform Benefiting from Structural Demand, Not Cycles
- Max Teh
- Apr 26
- 5 min read
Updated: 2 days ago
KEYPOINTS:
🔑 ResMed operates in a structurally underdiagnosed market where demand is driven by medical necessity, not economic cycles, supporting long-term compounding growth.
🔑 Its hardware-led model evolves into a high-margin recurring ecosystem, reinforced by patient adherence, provider integration, and data-driven compliance.
🔑 Trading at ~20× P/E, the stock is positioned to deliver a ~13–16% IRR over the coming 3-year period. This projected return is anchored in earnings compounding, requiring minimal dependency on valuation re-rating.
Table of contents
Disclaimer: This communication is provided for information purposes only and is not intended as a recommendation or a solicitation to buy, sell or hold any investment product. Readers are solely responsible for their own investment decisions.
1. A Business That Solves a Growing, Underdiagnosed Problem
ResMed operates in a category where demand is not discretionary — it is biologically driven.
Sleep apnea is not a lifestyle product; it is a chronic medical condition with direct links to:
Cardiovascular disease
Diabetes
Cognitive decline
Workplace productivity loss
Despite this, diagnosis rates remain structurally low.Estimates suggest that hundreds of millions globally remain undiagnosed, creating a long runway that is not dependent on economic cycles.
Unlike many healthcare names that rely on drug pipelines or binary outcomes, ResMed’s growth is driven by:
Increasing diagnosis rates
Expanding awareness among physicians
Broader insurance reimbursement coverage
This makes its demand curve steady, compounding, and structurally underpenetrated.
Importantly, this demand profile also makes the business relatively resilient through economic cycles. Sleep apnea treatment is not discretionary — patients do not pause therapy due to weaker consumer spending, and reimbursement structures further insulate demand from short-term macro volatility.
2. The Business Model: Hardware-Led, Recurring Ecosystem
At first glance, ResMed may appear to be a medical device company selling CPAP machines.
In reality, the model is more layered:
Initial device sale (CPAP / BiPAP machines)
Followed by recurring high-margin consumables:
Masks
Tubing
Filters
Over time, this creates:
A hybrid model combining elements of hardware + recurring revenue
Once a patient is onboarded:
Switching costs increase due to habit formation and therapy adherence
Providers are less incentivized to switch patients mid-treatment
ResMed benefits from repeat purchases of consumables
This dynamic is closer to a razor-and-blade model, with:
Lower-margin device entry
Higher-margin recurring revenue stream
3. Why This Category Is Structurally Sticky
What makes ResMed particularly durable is that:
The “product” is not just the device — it is the continuity of therapy
Sleep apnea treatment requires:
Daily usage
Long-term adherence
Consistency for health outcomes
This leads to:
High switching friction
Behavioral lock-in
Provider ecosystem reinforcement
Unlike consumer products where brand loyalty can be fickle, here:
Patients prioritize comfort and reliability
Providers prioritize proven efficacy and compliance tracking
ResMed’s integrated ecosystem — including cloud-based monitoring (AirView) — further strengthens this:
Doctors can track patient adherence remotely
Insurance reimbursement is tied to usage compliance
This creates a closed-loop system that competitors must replicate end-to-end, not just at the hardware level.
In addition, the nature of ResMed’s offering makes it less exposed to typical AI-driven disruption. The value lies in physical devices, regulated medical workflows, and long-term patient adherence — areas where software alone cannot easily substitute the core product. If anything, AI is more likely to enhance monitoring and compliance, reinforcing the existing ecosystem rather than displacing it.
4. The GLP-1 Concern: Structural Risk or Overstated Narrative?
A key debate around ResMed has been:
“Will GLP-1 drugs (e.g. Ozempic, Wegovy) reduce sleep apnea incidence?”
The logic:
Obesity is a major driver of sleep apnea
Weight loss drugs could reduce severity
While directionally valid, the market may be over-extrapolating near-term impact.
Key considerations:
1. Sleep apnea is multi-factorial
Not all cases are obesity-driven
Craniofacial structure, age, and genetics also play roles
2. Weight loss does not fully eliminate the condition
Many patients still require therapy post-weight reduction
3. Diagnosis tailwinds remain intact
Increased screening and awareness continue to drive new patients
4. Time lag between drug adoption and clinical outcomes
Even if GLP-1 adoption grows, the impact on apnea prevalence will likely be gradual
In this context:
GLP-1s are more likely to moderate growth at the margin, rather than disrupt the category.
5. Margin Expansion: A Less Obvious Driver
Beyond volume growth, ResMed has demonstrated:
Improving Operating margins
Operational leverage through scale
Part of this is cyclical (post-COVID supply chain normalization), but part is structural:
Higher mix of software and digital solutions
Recurring consumables contributing more to revenue
Pricing discipline within a medical reimbursement framework
This is important because:
Investors often assume medical device margins are static —but ResMed is quietly shifting toward a higher-quality earnings mix.
Read more about Resmed's future cost savings plans here.
6. Competitive Positioning: Difficult to Displace
ResMed operates in a relatively concentrated market, with a few key players (e.g., Philips Respironics).
However, competition is not purely price-based.
To meaningfully displace ResMed, a competitor must replicate:
Device reliability
Patient comfort and adherence
Physician trust
Digital monitoring ecosystem
Distribution and reimbursement relationships
This is not a single-product challenge — it is a system-level moat.
Additionally:
Past disruptions (e.g., Philips recall) have shown how fragile trust can be in this category
Once lost, it is difficult to rebuild
This further reinforces ResMed’s positioning as a trusted incumbent.
7. Valuation: A High-Quality Compounder with Moderate Return Expectations
ResMed is currently priced at approximately $205 per share, representing a ~20× P/E multiple. Given the company's operational visibility and overall quality, this valuation appears to be in a reasonable to attractive range.
The following base-case projections utilize conservative assumptions to estimate potential shareholder returns over a three-year horizon:
Annual Revenue Growth: Projected at ~8%, consistent with management's high-single-digit outlook.
Profitability Metrics: Gross margins are expected to remain stable at ~61%, with operating margins maintained at ~34%.
Capital Allocation: A ~1% annual reduction in share count is anticipated, bolstered by a share repurchase plan exceeding $600m for FY26. The dividend payout ratio is expected to be maintained at 20% annually.
Exit Multiple: Assuming the P/E multiple expands to 23x, the forecast indicates a potential Internal Rate of Return (IRR) reaching 16.2% over the next three years.
What This Implies
ResMed does not require aggressive assumptions to generate reasonable returns.However, it also does not naturally screen as a high-return opportunity within a 15–20% CAGR framework.
Instead, the investment case is more nuanced:
Returns are driven primarily by earnings compounding and capital returns,rather than multiple rerating or rapid growth acceleration.
This positions ResMed as:
A high-quality, lower-volatility compounder
With predictable earnings growth and margin stability
But limited upside without some degree of multiple expansion
🔗 refer to full model here.
8. Putting It Together
ResMed is a business where:
Demand is driven by medical necessity, not consumer preference
Growth is supported by underdiagnosis and aging demographics
The model benefits from recurring revenue and behavioral lock-in
Risks (e.g. GLP-1) are real but likely overstated in the near term
At the same time:
Return expectations should be calibrated appropriately
The opportunity is less about multiple rerating, and more about:
Steady compounding from a structurally advantaged position
Final Thought
ResMed is not trying to be a high-growth disruptor.
It is something arguably more valuable:
A mission-critical healthcare platform quietly compounding in the background —supported by structural demand, high switching costs, and an increasingly recurring business model.
Resmed Stock
Comments